We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Vicarious Surgical Inc | NYSE:RBOT | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
-0.0314 | -8.23% | 0.35 | 0.39 | 0.342 | 0.39 | 329,271 | 00:48:36 |
Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced financial results for the quarter ended September 30, 2023. Management will host a corresponding conference call at 4:30 p.m. ET today, November 13, 2023.
“The third quarter brought several successes for our business, but also introduced new challenges as we focused on the build and integration of our Version 1.0 System,” said Adam Sachs, Co-Founder and Chief Executive Officer. “While we were pleased with our ability to extend our cash runway through an equity follow-on offering and make meaningful progress on our individual sub-system builds, the impact from recent market-driven cost cutting initiatives combined with certain integration challenges have compelled us to revise our development schedule. We now expect to complete the Version 1.0 System build and integration during the Fall of 2024, and consequently anticipate a De Novo submission around early to mid 2026. Although there is still work ahead, we remain confident that our differentiated technology will allow us to revolutionize surgical robotics and transform the standard of care.”
Third Quarter 2023 Financial Results
Conference Call
Vicarious Surgical will host a conference call at 4:30 p.m. ET on Monday, November 13, 2023, to discuss its third quarter 2023 financial results. Investors interested in listening to the conference call may do so by dialing +1 (404) 975 4839 for domestic callers or +1 (929) 526 1599 for international callers, and using access code: 083118. A live and archived webcast of the event will be available at https://investor.vicarioussurgical.com.
About Vicarious Surgical
Founded in 2014, Vicarious Surgical is a next generation robotics company, developing a unique disruptive technology with the multiple goals of substantially increasing the efficiency of surgical procedures, improving patient outcomes, and reducing healthcare costs. The Company’s novel surgical approach uses proprietary human-like surgical robots to transport surgeons inside the patient to perform minimally invasive surgery. The Company is led by an experienced team of technologists, medical device professionals and physicians, and is backed by technology luminaries including Bill Gates, Vinod Khosla’s Khosla Ventures, Innovation Endeavors, Jerry Yang’s AME Cloud Ventures, Sun Hung Kai & Co. Ltd and Philip Liang’s E15 VC. The Company is headquartered in Waltham, Massachusetts. Learn more at www.vicarioussurgical.com.
Use of Non-GAAP Financial Measures
In addition to providing financial measurements that have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”), Vicarious Surgical provides additional financial metrics that are not prepared in accordance with U.S. GAAP (“non-GAAP”). The non-GAAP financial measures included in this press release are Adjusted Net Loss and Adjusted Net Loss Per Share (“Adjusted EPS”, and together with Adjusted Net Loss, “Non-GAAP Financial Measures”). The Company presents Non-GAAP Financial Measures in order to assist readers of its consolidated financial statements in understanding the core operating results that its management uses to evaluate the business and for financial planning purposes. Vicarious Surgical’s Non-GAAP financial measures provide an additional tool for investors to use in comparing its financial performance over multiple periods.
Adjusted Net Loss and Adjusted EPS are key performance measures that Vicarious Surgical’s management uses to assess its operating performance. These Non-GAAP Financial Measures facilitate internal comparisons of Vicarious Surgical’s operating performance on a more consistent basis. Vicarious Surgical uses these performance measures for business planning purposes and forecasting. Vicarious Surgical believes that the Non-GAAP Financial Measures enhance an investor’s understanding of Vicarious Surgical’s financial performance as it is useful in assessing its operating performance from period-to-period, by excluding certain items that Vicarious Surgical believes are not representative of its core business.
The Non-GAAP Financials Measures may not be comparable to similarly titled measures of other companies because they may not calculate this measure in the same manner. Adjusted Net Loss and Adjusted EPS are not prepared in accordance with U.S. GAAP and should not be considered in isolation of, or as an alternative to, measures prepared in accordance with U.S. GAAP. When evaluating Vicarious Surgical’s performance, you should consider the Non-GAAP Financial Measures alongside other financial performance measures prepared in accordance with U.S. GAAP, including net loss.
The Non-GAAP Financial Measures do not replace the presentation of Vicarious Surgical’s U.S. GAAP financial results and should only be used as a supplement to, not as a substitute for, Vicarious Surgical’s financial results presented in accordance with U.S. GAAP. In this press release, Vicarious Surgical has provided a reconciliation of Adjusted Net Loss to net loss, the most directly comparable U.S. GAAP financial measure, and the calculation for Adjusted EPS.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The company’s actual results may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. All statements other than statements of historical facts contained herein, including without limitation the quotations of our Chief Executive Officer regarding Vicarious Surgical’s opportunity, among other things, are forward-looking statements that reflect the current beliefs and expectations of management. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside Vicarious Surgical’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: changes in applicable laws or regulations; the ability of Vicarious Surgical to raise financing in the future; the success, cost and timing of Vicarious Surgical’s product and service development activities; the potential attributes and benefits of Vicarious Surgical’s product candidates and services; Vicarious Surgical’s ability to obtain and maintain regulatory approval for the Vicarious System on the timeline it expects, and any related restrictions and limitations of any approved product; the size and duration of human clinical trials for the Vicarious Surgical; Vicarious Surgical’s ability to identify, in-license or acquire additional technology; Vicarious Surgical’s ability to maintain its existing license, manufacture, supply and distribution agreements and scale manufacturing of the Vicarious Surgical System and any future product candidates to commercial quantities; Vicarious Surgical’s ability to compete with other companies currently marketing or engaged in the development of products and services that Vicarious Surgical is currently marketing or developing, as well as with the use of open surgeries; the size and growth potential of the markets for Vicarious Surgical’s product candidates and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of Vicarious Surgical’s product candidates and services and reimbursement for medical procedures conducted using its product candidates and services; the company’s ability to meet its estimates regarding expenses, revenue, capital requirements, cash runway and needs for additional financing; Vicarious Surgical’s financial performance; Vicarious Surgical’s intellectual property rights, its ability to protect or enforce these rights, and the impact on its business, results and financial condition if it is unsuccessful in doing so; economic downturns, political and market conditions and their potential to adversely affect Vicarious Surgical’s business, financial condition and results of operations; the impact of COVID-19 on Vicarious Surgical’s business; and other risks and uncertainties indicated from time to time in Vicarious Surgical’s filings with the SEC. Vicarious Surgical cautions that the foregoing list of factors is not exclusive. The company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Vicarious Surgical does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.
VICARIOUS SURGICAL INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(in thousands, except per share data)
Three Months Ended September 30,
Nine Months Ended September 30,
2023
2022
2023
2022
Operating expenses:
Research and development
$
13,040
$
12,120
$
39,110
$
32,023
Sales and marketing
1,401
1,912
5,027
4,625
General and administrative
6,911
8,130
20,988
22,820
Total operating expenses
21,352
22,162
65,125
59,468
Loss from operations
(21,352
)
(22,162
)
(65,125
)
(59,468
)
Other income (expense):
Change in fair value of warrant liabilities
4,703
(3,038
)
3,705
75,291
Interest and other income
946
494
3,463
603
Interest expense
(1
)
(31
)
(3
)
(89
)
Income/(loss) before income taxes
(15,704
)
(24,737
)
(57,960
)
16,337
Provision for income taxes
—
—
—
—
Net income/(loss)
$
(15,704
)
$
(24,737
)
$
(57,960
)
$
16,337
Net income/(loss) per share of Class A and Class B common stock, basic
$
(0.10
)
$
(0.20
)
$
(0.43
)
$
0.14
Net income/(loss) per share of Class A and Class B common stock, diluted
$
(0.10
)
$
(0.20
)
$
(0.43
)
$
0.12
Weighted average shares, basic
155,141,393
121,965,277
136,194,179
121,201,693
Weighted average shares, diluted
155,141,393
121,965,277
136,194,179
131,102,132
Other comprehensive income/(loss):
Net unrealized income/(loss) on investments
41
—
(89
)
—
Other comprehensive income/(loss)
41
—
(89
)
—
Comprehensive net income/(loss)
$
(15,663
)
$
(24,737
)
$
(58,049
)
$
16,337
VICARIOUS SURGICAL INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
(in thousands, except share and per share data)
September 30,
December 31,
2023
2022
Assets
Current assets:
Cash and cash equivalents
$
59,113
$
116,208
Short-term investments
51,076
$
—
Prepaid expenses and other current assets
3,222
4,196
Total current assets
113,411
120,404
Restricted cash
936
936
Property and equipment, net
5,889
6,586
Right-of-use assets
11,669
12,273
Other long-term assets
146
92
Total assets
$
132,051
$
140,291
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable
$
1,529
$
1,731
Accrued expenses
5,267
5,808
Lease liabilities, current portion
1,007
838
Current portion of equipment loans
—
16
Total current liabilities
7,803
8,393
Lease liabilities, net of current portion
14,060
14,832
Warrant liabilities
2,316
6,021
Total liabilities
24,179
29,246
Stockholders’ equity:
Class A Common stock
15
11
Class B Common stock
2
2
Additional paid-in capital
227,545
172,673
Accumulated other comprehensive loss
(89
)
—
Accumulated deficit
(119,601
)
(61,641
)
Total stockholders’ equity
107,872
111,045
Total liabilities and stockholders’ equity
$
132,051
$
140,291
VICARIOUS SURGICAL INC.
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
(in thousands, except share and per share data)
Adjusted net loss and Adjusted EPS
Three Months Ended September 30,
Six Months Ended September 30,
2023
2022
2023
2022
Net income/(loss)
$
(15,704
)
$
(24,737
)
$
(57,960
)
$
16,337
Change in fair value of warrant liabilities
4,703
(3,038
)
3,705
75,291
Adjusted net loss
(20,407
)
(21,699
)
(61,665
)
(58,954
)
Adjusted EPS, basic and diluted
$
(0.12
)
$
(0.18
)
$
(0.45
)
$
(0.49
)
Weighted average shares, basic and diluted
155,141,393
121,965,277
136,194,179
121,201,693
View source version on businesswire.com: https://www.businesswire.com/news/home/20231113763588/en/
Investor Contact Kaitlyn Brosco Vicarious Surgical Kbrosco@vicarioussurgical.com
Marissa Bych Gilmartin Group Marissa@gilmartinir.com
Media Inquiries Abby Mayo for Matter Health media@vicarioussurgical.com
1 Year Vicarious Surgical Chart |
1 Month Vicarious Surgical Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions